UK Markets close in 5 hrs 25 mins

Syros Pharmaceuticals, Inc. (0LC7.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.8362-0.1138 (-11.98%)
As of 03:01PM BST. Market open.
Full screen
Previous close0.9500
Open0.8362
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.8362 - 0.8362
52-week range0.8362 - 0.8362
Volume100
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)1.87
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

    CAMBRIDGE, Mass., August 09, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update.

  • Business Wire

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., August 04, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock unit (RSU) award for 31,000 shares of Syros common stock to one newly hired employee in connection with the employee’s commencement of employment with Syros. These RSUs were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire

    Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

    CAMBRIDGE, Mass., August 03, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan drug designation for tamibarotene for the treatment of myelodysplastic syndrome (MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination wit